Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/063757external-prioritypatent/WO2014207232A1/en
Application filed by Roche Innovation Ct Copenhagen AsfiledCriticalRoche Innovation Ct Copenhagen As
Publication of CR20150662ApublicationCriticalpatent/CR20150662A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere a compuestos oligoméricos y conjugados de los mismos con diana en el ARNm de la proproteína-convertasa subtilisina/kexina tipo 9 (PCSK9) en una célula, que conducen a una expresión reducida de PCSK9. La reducción de la expresión de PCSK9 resulta beneficiosa para un abanico de trastornos médicos, tales como la hipercolesterolemia y trastornos relacionados.The present invention relates to oligomeric compounds and conjugates thereof with target in the mRNA of proprotein-convertase subtilisin / kexin type 9 (PCSK9) in a cell, which lead to reduced expression of PCSK9. The reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
CR20150662A2013-06-272015-12-14
OLIGÓMEROS ANTISENTIDO AND CONJUGADOS WITH DIANA IN PCSK9
CR20150662A
(en)